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Anticonvulsant treatment is associated with a high prevalence of reproductive 
dysfunction compared with age-matched non-epileptics. The contributions from 
reproductive endocrine effects of anticonvulsant drugs relative to other factors 
including the convulsions, underlying neurological disease, and psychosocial 
concomitants remains difficult to disentangle. We examined the widely used 
anticonvulsants valproate (VPA) and carbamazepine (CBZ) for steroidal bioactivity 
using yeast-based steroid receptor-reporter system. In vitro bioassays for reproductive 
steroids were established by stably transforming yeast cells with human cDNA for 
androgen receptor (AR), progesterone receptor A (PR) or estrogen receptor  (ER) 
together with a reporter plasmid containing a ß-galactosidase gene under 
transcriptional control of an androgen (ARE), progestin (PRE) or estrogen (ERE) 
reporter element. Bioassays were performed by culturing yeast in the absence 
(agonist bioassay) or presence (antagonist bioassay) of cognate ligands (5 nmol/L 
testosterone for AR,  1.6 nmol/L progesterone for PR and 5 nmol estradiol for ER) for 
4 (PR) or 16 (AR, ER) hours using ß-galactosidase activity in yeast cell lysates as the 
end-point. VPA showed dose-dependent inhibition of progesterone-induced PR- and 
testosterone-induced AR activity. VPA had no ER antagonist bioactivity nor any AR, 
PR or ER agonist bioactivity. CBZ had no significant agonist or antagonist AR, PR or 
ER bioactivity. We conclude that VPA is a non-steroidal antagonist for human AR and 
PR but not ER. VPA’s androgen and progesterone antagonism at concentrations 
much lower than therapeutic blood levels (350-700 M) seems likely to contribute to 





Epilepsy is associated with a high prevalence of reproductive dysfunction in men (1) 
and women (2, 3). These disorders include subfertility, anovulation, menstrual 
disturbance, hyperandrogenism, lowered effectiveness of oral contraception, adverse 
pregnancy outcomes in women (2, 3)  and sexual dysfunction, androgen deficiency 
symptoms, testicular atrophy, impaired spermatogenesis and subfertility in men (1) 
compared with age-matched non-epileptics. These effects appear to be multifactorial 
with reproductive endocrine effects due to anti-convulsant drugs and epilepsy itself as 
well as psychosocial factors all contributing to the high prevalence of reproductive 
disorders.  
 
Among anticonvulsants, carbamazepine (CBZ) and valproate (VPA) are among the 
two most widely used. In epileptic patients, increased blood steroid hormone binding 
globulin (SHBG) concentrations are the most consistent change observed in 
reproductive endocrine parameters with anticonvulsant drugs (4, 5). Increased SHBG 
reduces metabolic clearance of testosterone (6) and could thereby impair endogenous 
sex steroid action. It is unlikely, however, this is sufficient to explain the diversity of 
reproductive disorders of patients on long-term anticonvulsants (1-3) and other 
pathogenic mechanisms are likely to be involved.  
 
The possibility that CBZ and VPA may have reproductive endocrine effects due to 
interaction of these drugs with the sex hormone receptors, androgen receptor (AR), 
estrogen receptor (ER) and progesterone receptor (PR) has not been evaluated. All 
three receptors belong to a large superfamily of nuclear hormone receptors that share 
a well-conserved DNA-binding domain (DBD), a structurally conserved ligand-binding 
domain (LBD) and an N-terminal domain with no homology between the different 
receptors (7). After ligand binding, the receptor dimerizes and binds to hormone 
response elements located within the promoters of hormone-responsive genes to act 
as a ligand-activated transcription factor. Drugs can interfere with this receptor-
mediated process by many potential mechanisms including altering blood hormone 
levels (via changes in synthesis, distribution, metabolism or clearance), modifying 
steroid receptor expression levels, directly binding to the receptor to mimic or block 
steroid function or interacting with post-receptor co-regulator proteins. So far only the 
first possibility has been considered in any detail. We therefore utilised a system 
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whereby each of the mammalian sex steroid receptors are stably introduced into the 
yeast strain Saccharomyces cerevisae to function as steroid-dependent transcription 
activators.  This yeast reporter assays can then serve as useful tools for studying 
mammalian steroid receptor function.   In the present study, therefore we used yeast-
based AR, PR or ER in-vitro bioassays to investigate potential interactions of CBZ or 
VPA with these sex steroid hormone receptors. We show that VPA, but not CBZ, 
antagonizes both AR and PR action without effects on ER. 
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MATERIALS AND METHODS 
 
Materials 
Hormones, valproate and carbamazapine were obtained from Sigma-Aldrich (Castle 
Hill, NSW, Australia) and dissolved in ethanol for stock concentrations.  
 
Plasmids and Reporter Gene Constructs 
The full-length hPR cDNA plasmid and the PRE-ß-galactosidase reporter plasmid 
were kindly provided by Professor DP McDonnell. Yeast strain YPH500 (MATa, ura3-
52, lys2-801, ade2-101, trp1-63, his3-200, leu2-1) was co-transformed with both 
plasmids by standard alkali-transformation (Alkali cation yeast transformation kit, 
BIO101 systems, Qbiogene Inc., Carlsbad, CA, USA).  Co-transformant yeast strains 
were selected by tryptophan and uracil auxotrophy.  Yeast strains (1) YPH500 
transformed with YEpE22 and YRpE2 and  (2) YPH500 transformed with YEpAR and 
YPpG2 were also kindly provided by Professor DP McDonnell.   
 
Yeast culture 
Yeast transformants were grown overnight at 30C with vigorous orbital shaking at 
300 rpm in CSM-leu-ura (ER,AR BIO101) or CSM-trp-ura (PR, BIO101).  Following 
overnight culture, the yeast culture was subcultured in fresh medium and allowed to 
grow until early-mid-log phase (OD600nm ~1.0). 
 
Estrogen, progesterone and androgen receptor assays 
For AR and ER bioassays, yeast from early-mid-log phase growth were diluted (to 
OD600=1.0) in selective medium (CSM-leu-ura) plus 100 M CuSO4 to induce 
receptor production. For the PR bioassay, yeast were diluted (to OD600=0.7) in 
selective medium (CSM-trp-ura). Diluted yeast were aliquoted into 24-well culture 
plates (500 l/well) and 5 l doses of steroid or drug were added. For antagonism 
experiments, 5l of testosterone (5X10-9 M) or progesterone (1.6X10-9 M) or estradiol 
(5X10-9 M) and 5 l of valproate or carbamazapine (1X10-7 M) were added. Each 
assay included testosterone (AR), progesterone (PR) or estradiol (ER) standard curve 
as well as a vehicle (0.1% ethanol) control. Multiwell plates were incubated at 30C 
with shaking for either overnight (AR & ER) or 4 hr (PR).  After incubation, the yeast 
culture samples were washed in assay buffer, lysed and extract assayed for -
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galactosidase. Dose-responses were fitted to a 4 parameter sigmoid curve using 
nonlinear regression option in Sigmaplot version 8.  
 
ß-galactosidase assay 
After incubation, the yeast culture samples were transferred to 1.7 ml microcentrifuge 
tubes, centrifuged at 3,000 rpm, and the cells resuspended in 250 l of assay buffer 
(60 mM Na2HPO4, 40 mM NaH2PO4, 10 mM KCl, 1 mM MgSO4,).  Cells were 
incubated on ice for 15 mins and then lysed by vortexing in the presence of 4.5 l 
0.1% SDS and 9 l chloroform.  Lysate was then warmed to 30C (5 mins) before 30 
l ONPG (4mg/ml) added and incubated at 30C until formation of yellow color.  
Reaction was stopped with addition of 75 l sodium carbonate (1M).  The exact time 
was recorded.  The yellow color (ONPG cleavage) was measured at OD420 and OD550.  




Results of the experimental studies are reported as mean+SE compared to controls.  
Unpaired Student’s t-tests were used to determine the significance of changes 





The dose-response characteristics of the yeast PR, AR and ER bioassays were 
established by measuring the response to the receptor’s cognate ligands 
progesterone, testosterone and estradiol, respectively, over the steroid concentration 
range from 10-6 M to 10-16 M (Figure 1).   
 
The potential agonist activity of carbamazepine and valproate were evaluated at 10 
M concentration.  Neither drug produced nonspecific yeast cell toxicity at this dose.  
Neither carbamazepine nor valproate displayed agonist activity for any of the 3 steroid 
hormone receptors (Figure 2). 
 
The antagonist activity of carbamazepine and valproate were evaluated at 10 M 
concentration in the presence of mid-range doses (~EC50) of the appropriate hormone 
(5 nmol/L testosterone, 1.6 nmol/L progesterone, 5 nmol/L estradiol).  Maximal effects 
of valproate (100 M) achieved blockade of AR activity to 40%- and PR activity to 
~22% of EC50-induced PR activity.  Carbamazepine showed no antagonist effects.  
Neither valproate or carbamazepine demonstrated antagonism at the ER (Figure 3). 
 
We further characterized the antagonist activity of valproate by determining the effects 
of lower concentrations of valproate on testosterone-, dihydrotestosterone- and 
progesterone- inducing activity (Figure 4).  VPA demonstrated a dose-dependent 
blockade of AR activity with first significant effect at 30 M for both testosterone and 
dihydrotestosterone.  VPA also showed dose-dependent inhibition of progesterone-





Reproductive dysfunction including subfertility (8-10) and disruption of reproductive 
endocrine function including menstrual disturbances and anovulation, 
hyperandrogenism and polycystic ovary (PCO)-like syndrome  in women (11-13) and 
sexual dysfunction and androgen deficiency in men (1) are common in patients with 
epilepsy. The role of anticonvulsant drugs in these diverse reproductive disorders 
remains unclear as most clinical studies have been observational and relatively small. 
Nevertheless, prospective studies demonstrate endocrine effects of antiepileptic drugs 
the most consistent being increased blood SHBG concentration (4, 5, 14, 15), 
although the mechanism remains unknown. Other endocrine changes are not readily 
explained solely by increased blood SHBG concentrations.  
 
Valproate is among the most frequently prescribed anticonvulsant drugs used by more 
than 2 million people daily (16). Its role in the reproductive endocrine disturbances 
frequently present in men and women with epilepsy is controversial (1, 11, 13, 16). As 
well as a broad spectrum of antiepileptic drug, valproate is also prescribed as a mood 
stabiliser for bipolar disorders, for neuropathic pain including headache and for 
migraine prophylaxis (17, 18). The present study shows that VPA, at concentrations 
much lower than therapeutic blood levels, blocks AR and PR, but not ER, action in an 
in-vitro bioassay. By contrast, carbamazepine had no detectable agonist or antagonist 
steroidal bioactivity and neither VPA nor CBZ had any sex steroid agonist activity in 
vitro. These findings indicate that valproate may produce clinical effects as an anti-
androgen and anti-progestin when used as an anticonvulsant.  
 
The low fertility of women with epilepsy (9, 10, 19) has many contributing factors 
including social as well as biological factors. The strong PR antagonism by valproate, 
detectable at 10 M and nearly complete at 100 M compared with blood therapeutic 
concentrations of 350-700 M, suggests some biological effects in women may be at 
least partly due to impaired PR-mediated progesterone action on reproductive tissues 
notably the uterus, breast and ovary. The anti-progestin effects of valproate may be a 
previously unrecognised factor contributing to the low fertility of women with epilepsy, 
notably to their otherwise unexplained higher rates of apparent miscarriage (8). In 
addition, anti-progestin effects may contribute to the higher frequency of anovulation 
among valproate-treated women with epilepsy (20) as mice null for PRA, but not PRB, 
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fail to ovulate (21, 22). Further studies are required to clarify the contribution and 
mechanism of valproate in lowering reproductive potential of women with epilepsy or 
bipolar mood disorder. Apart from progesterone’s role as a universal precursor on the 
steroidogenic pathway, there is no known role of progesterone mediated via a 
progesterone receptor in men so there are no known or likely male reproductive health 
effects of the anti-progestin effects of valproate.  
 
The anti-androgenic effects of valproate are most likely to be manifest in men with 
epilepsy. These effects might contribute to the delayed puberty (23), impaired 
reproductive function and androgenic effects (1) reported in males with epilepsy. The 
most characteristic biochemical effects expected for a drug with pure anti-androgen 
properties would be increases in blood testosterone and LH (and to a lesser extent 
FSH) concentrations (24) comparable with the findings in androgen insensitivity due to 
an inactivated androgen receptor (25) or treatment with non-steroidal anti-androgen 
(26, 27). Such findings are reported in hormonal studies of men with epilepsy with 
control non-epileptic populations (5, 28-30). The alternative interpretation of such anti-
androgenic effects is attributing them to increased blood SHBG concentrations, and 
consequently lowered “free” or biologically active testosterone, remains speculative.  
 
The more prominent effects of valproate compared with carbamazepine is consistent 
with the clinical evidence that valproate treatment is associated with greater disruption 
of reproductive endocrine function than other anticonvulsant drugs (11, 15, 31). 
Similarly, valproate treatment for other conditions such as bipolar mood disorders and 
migraine is also associated with similar disruption of reproductive endocrine function 
to a greater extent than other treatments (32, 33). Nevertheless, the available clinical 
studies are limited in explanatory power due to their mostly observational design and 
small sample size. Previous mechanistic studies have shown valproate has endocrine 
effects such as activation of PPAR (34), demethylation of DNA in an in vitro cell 
model (35),  modulation of GABA-ergic neuronal input to the hypothalamus (36, 37) 
and a range of metabolic effects notably increasing blood leptin and insulin, but 
decreasing IGFBP1, levels (11, 32, 38, 39).  
 
Whether the anti-androgenic effects of valproate have any clinical significance in 
women, where blood androgens are normally at levels equivalent to castrate men or 
children remains doubtful. At the level of the ovarian follicle these effects may 
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stimulate ovarian androgen synthesis (38) as well as inhibiting follicular aromatization 
(40, 41). In normal non-epileptic rats, long-term VPA treatment induced endocrine 
changes and increased the number of ovarian follicular cysts (42). Similarly, in male 
rats high doses of valproate retards fertility, inhibit fertility, testicular weight and 
spermatogenesis as well as epididymal and prostate weight in rodents and larger 
mammals (43-48). While these changes are likely to be due to the lowered blood 
testosterone concentrations, valproate does not directly inhibit androgen biosynthesis 
(49, 50). The findings of increased LH and FSH in some (42) but not all (46) studies is 
consistent with valproate’s anti-androgen action in an in-vitro bioassay.  
 
In conclusion, we have shown using a yeast-based in-vitro bioassay for steroid 
hormones that VPA, a commonly used anticonvulsant for treatment of epilepsy and 
bipolar disorder, is an antiandrogen and antiprogestin but has no antiestrogen effects. 
These effects of VPA are evident at concentrations well below therapeutic blood 
concentrations of valproate when used to treat epilepsy or bipolar mood disorder.  By 
contrast, carbemazapine had no sex steroid hormone receptor bioactivity. These 
findings suggest a new reproductive endocrine mechanism for valproate in the 
frequent reproductive dysfunction reported in valproate treated patients.  
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Figure 1: Yeast bioassay for AR, PR and ER activity. (A) Dose response curve for 
testosterone induced AR activity.  Testosterone (dose range 10-6 to 10-16 M) was 
added to yeast cultures for an incubation period of 24 hours before the culture media 
assayed for -galactosidase activity.  Values represent the mean + SE of 6 separate 
experiments.  (B) Dose response curve for progesterone induced PRA activity.  
Progesterone (dose range 10-6 to 10-16 M) was added to yeast cultures for an 
incubation period of 4 hours before culture media assayed for -galactosidase activity.  
Values represent the mean + SE for 6 separate experiments.  (C) Dose response 
curve for estradiol induced ER activity.  Estradiol (dose range 10-6 to 10-16 M) was 
added to yeast cultures for an incubation period of 24 hours before culture media 
assayed for -galactosidase activity. Values represent the mean + SE of 3 separate 
experiments.  All curves are presented as the % of maximal -galactosidase activity. 
 
Figure 2: The effects of CBZ and VPA on androgen, progesterone and estrogen 
bioassays.  (A) AR agonist activity of CBZ and VPA relative to EC50 testosterone dose 
(5 X 10-9 M).  Yeast cultures were treated with either 10 X 10-6M CBZ or VPA or 5 X 
10-9 M testosterone and incubated for 24 hours.  Following incubation, -galactosidase 
activity was assayed and values represent the mean + SE of 3 separate experiments.  
Values are expressed as % of 5 X 10-9 M testosterone-induced -galactosidase 
activity.  (B) PR agonist activity of CBZ and VPA relative to EC50 dose of progesterone 
(1.6 X 10-9 M).  Yeast cultures were treated with either 10 X10-6 M CBZ or VPA or 1.6 
X 10-9 M progesterone and incubated for 4 hours.  Following incubation, -
galactosidase activity was assayed and values represent the mean + SE of 3 separate 
experiments.  Values are expressed as % of 1.6 X 10-9 M progesterone-induced -
galactosidase activity. (C) ER agonist activity of CBZ and VPA relative to EC50 dose of 
estradiol (5 X 10-9 M).  Yeast cultures were treated with either 10 X 10-6 M CBZ or 
VPA or 5 X 10-9 M estradiol and incubated for 24 hours.  Following incubation, -
galactosidase activity was assayed and values represent the mean + SE of 3 separate 




Figure 3: VPA inhibitory action in androgen and progesterone, but not estrogen, 
bioassays. (A) VPA antagonism of testosterone-induced AR activity.  Yeast cultures 
were incubated for 24 hours with 5 X 10-9 M testosterone in the presence of 10 X 10-6 
M valproate or 10 X 10-6 M carbamazepine.  Values represent mean + SE of 4 
separate experiments and are presented as % of 5 X 10-9 M testosterone-induced -
galactosidase activity. *p<0.05.  (B) VPA antagonism of progesterone-induced PR 
activity.  Yeast cultures were incubated for 4 hours with 1.6 X 10-9 M progesterone in 
the presence of 10 X 10-6 M valproate or 10 X 10-6 M carbamazepine.  Values 
represent mean + SE or 4 separate experiments and are presented as % of 1.6 X 10-9 
M progesterone-induced -galactosidase activity. *p<0.005.  (C)  No antagonism of 
estradiol-induced ER activity by VPA or CBZ. Yeast cultures were incubated for 24 
hours with 5 X 10-9 M estradiol in the presence of 10 X 10-6 M valproate or 10 X 10-6 M 
carbamazepine.  Values represent mean + SE or 4 separate experiments and are 
presented as % of 5 X 10-9 M estradiol-induced -galactosidase activity. 
 
Figure 4:  Dose-dependent inhibition by increasing concentrations of valproate of 
progesterone (), testosterone ()or dihydrotestosterone () stimulated yeast cells.  
Yeast were cultured in the presence of 5 X 10-9 M testosterone or dihydrotesterone or 
1.6 X10-9 M progesterone together with 1 - 10 X 10-6 M valproate.  Values represent 
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VPA dose response curves
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